工程化提高凝血因子VIII亲和力的重组VWF D'D3白蛋白融合蛋白效力增强
本研究通过定向和随机诱变哺乳动物展示平台,获得对凝血因子VIII亲和力增强的重组VWF D'D3白蛋白融合蛋白变体。在大鼠临床前研究中,这些变体以更低剂量即可达到等效的rVIII-SingleChain半衰期延长,并在体外显示酸性内体中解离减少、FcRn再循环更高效。
要点
- 改造rD'D3-FP提高对FVIII亲和力可减少与内源性VWF交换。
- 高亲和力变体在大鼠中以更低剂量延长rVIII-SingleChain半衰期。
- 变体在酸性内体中减少解离并增强FcRn介导的共再循环。
核心结论
- rD'D3-FP变体在潜在临床剂量下对共给药FVIII的剂量水平和半衰期延长有明显获益,支持其用于治疗A型血友病的开发。
研究设计与样本
- 采用定向诱变和随机诱变结合新型哺乳动物展示平台筛选rD'D3-FP变体,并在体外和大鼠临床前研究中评估。
主要发现
- 在大鼠临床前研究中,对FVIII亲和力增强的rD'D3-FP变体显示出增强的效力,达到等效rVIII-SingleChain半衰期延长所需的剂量水平降低。
- 在体外细胞成像研究中,rVIII-SingleChain从rD'D3-FP变体在酸性内体中解离减少,并通过FcRn再循环系统更高效地共再循环rD'D3-FP/rVIII-SingleChain复合物。
临床怎么用
- 提示可通过工程化提高rD'D3-FP对FVIII的亲和力,以更低剂量实现FVIII半衰期延长,支持A型血友病治疗开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have recently reported on a recombinant von Willebrand factor (VWF) D'D3 albumin fusion protein (rD'D3-FP) developed to extend the half-life of coagulation factor VIII (FVIII) for the treatment of hemophilia A. Based on predictive modelling presented in this study, we hypothesized that modifying rD'D3-FP to improve FVIII interaction would reduce exchange with endogenous VWF and provide additional FVIII half-life benefit. OBJECTIVES: The aim of this study was to identify novel rD'D3-FP variants with enhanced therapeutic efficacy in extending FVIII half-life. METHODS: Through both directed mutagenesis and random mutagenesis using a novel mammalian display platform, we identified novel rD'D3-FP variants with increased affinity for FVIII (rVIII-SingleChain) under both neutral and acidic conditions and assessed their ability to extend FVIII half-life in vitro and in vivo. RESULTS: In rat preclinical studies, rD'D3-FP variants with increased affinity for FVIII displayed enhanced potency, with reduced dose levels required to achieve equivalent rVIII-SingleChain half-life extension. In cell-based imaging studies in vitro, we also demonstrated reduced dissociation of rVIII-SingleChain from the rD'D3-FP variants within acidic endosomes and more efficient co-recycling of the rD'D3-FP/rVIII-SingleChain complex via the FcRn recycling system. CONCLUSIONS: In summary, at potential clinical doses, the rD'D3-FP variants provide marked benefits with respect to dose levels and half-life extension of co-administered FVIII, supporting their development for use in the treatment of hemophilia A.
引用
- Chia J, Pestel S, Glauser I, et al. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII. J Thromb Haemost. 2021. PMID: 34333849. doi:10.1111/jth.15480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。